11 completed, 4 terminated, 1 withdrawn. 9 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 3 |
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow bermekimab: new trials by email Literature Review of bermekimab trials Research Report on bermekimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants JNJ-77474462 - Healthy | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2023-05-01 | 2025-02-03 | |
| A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa Bermekimab, Adalimumab, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Janssen Research & Development, LLC | 151 | 2021-10-12 | 2023-11-13 |
| A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Bermekimab, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 6 | 2021-09-02 | 2023-05-24 |
| A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Placebo, Bermekimab, Dupilumab - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 199 | 2021-05-03 | 2023-03-01 |
| A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses JNJ-77474462, Placebo - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 24 | 2020-10-16 | 2021-09-29 |
| A Study of JNJ-77474462 in Healthy Participants JNJ-77474462, Anakinra - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 78 | 2020-10-13 | 2023-06-29 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa bermekimab, placebo - Hidradenitis Suppurativa, Acne Inversa | Phase 2 | Completed | Janssen Research & Development, LLC | 153 | 2019-09-16 | 2023-07-27 |
| The Benefit of Bermekimab in Patients With Systemic Sclerosis MABp1 (Bermekimab) OR Placebo, MABp1 (Bermekimab) - Scleroderma, Systemic | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 20 | 2019-07-19 | 2022-09-29 |
| Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia Xilonix plus Onivyde and 5FU - Pancreatic Cancer, Cachexia | Phase 1 | Completed | Andrew Hendifar, MD | 16 | 2017-10-16 | 2020-12-30 |
| A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer Xilonix, Placebo - Symptomatic Colorectal Cancer, Advanced Colorectal Cancer | Phase 3 | Completed | Janssen Research & Development, LLC | 276 | 2014-07-31 | 2021-03-01 |
| A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Xilonix - Pyoderma Gangrenosum | Phase 2 | Completed | Janssen Research & Development, LLC | 10 | 2014-01-31 | 2025-07-08 |
| A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer Xilonix, Placebo - Metastatic Colorectal Cancer | Phase 3 | Terminated | Janssen Research & Development, LLC | 643 | 2013-03-31 | 2021-06-29 |
| Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris RA-18C3 - Acne Vulgaris | Phase 2 | Completed | Janssen Research & Development, LLC | 11 | 2012-02-29 | 2025-03-30 |
| Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis RA-18C3 - Psoriasis | Phase 2 | Completed | Janssen Research & Development, LLC | 8 | 2011-09-30 | 2025-03-30 |
| Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis. CV-18C3, Standard of Care - Patients Undergoing Repeat Peripheral Artery Revascularization | Phase 2 | Completed | Janssen Research & Development, LLC | 43 | 2011-06-30 | 2025-03-30 |
| Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies CA-18C3 - Hematologic Malignancies | Phase 1 | Completed | Janssen Research & Development, LLC | 14 | 2011-04-30 | 2021-02-16 |
Colorectal Neoplasms (2) · Dermatitis, Atopic (2) · Hidradenitis Suppurativa (2) · Acne Vulgaris (1) · Adenocarcinoma (1) · Cachexia (1) · Disease (1) · Hematologic Neoplasms (1) · Pancreatic Neoplasms (1) · Psoriasis (1) · Pyoderma Gangrenosum (1) · Scleroderma, Systemic (1) · Weight Loss (1)
Janssen Research & Development, LLC (14) · Andrew Hendifar, MD (1) · Hellenic Institute for the Study of Sepsis (1)
United States (11) · Australia (4) · Poland (4) · Canada (2) · Germany (2) · Japan (2) · Netherlands (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Czechia (1) · Greece (1) · Hungary (1) · Israel (1)
Andrew Hendifar, MD (1) · Hosam El-Sayed, M.D., Ph.D. (1) · Johann Gudjonsson, M.D., PhD (1) · Michael D Stecher, MD (1)